The estimation of carcinogenic risks from exposure to chemicals has become an integral part of the regulatory process in the United States within the past decade. With it have come considerable controversy and debate over the scientific merits and shortcomings of the methods and their impact on risk management decisions. In this paper we highlight selected topics of current interest in the debate. As an indication of the level of public concern, we note the major recent reports on risk assessment from the National Academy of Sciences and the U.S. Environmental Protection Agency's proposed substantial revisions to its Guidelines for Carcinogen Risk Assessment. We identify and briefly frame several key scientific issues in cancer risk assessment, including the growing recognition of the importance of understanding the mode of action of carcinogenesis in experimental animals and in humans, the methodologies and challenges in quantitative extrapolation of cancer risks, and the question of how to assess and account for human variability in susceptibility to carcinogens. In addition, we discuss initiatives in progress that may fundamentally alter the carcinogenesis testing paradigm.
Introduction
Although risk assessment in various forms has been used since antiquity, its use to assess and regulate the carcinogenic hazards of environmental chemicals in the United States dates to the early 1970s (1) (2) (3) (4) (5) (11) , released for public comment in April 1996, have proposed several changes that should, if adopted, allow a more flexible process based on the best available science.
In the following paragraphs we highlight some of the scientific issues that are the focus of the current discussion.
Mode of Action (11) provide a framework for the use of such scientific information, when available, in place of the default assumptions that have characterized most cancer risk assessments in the past.
Specifically, the guidelines call for the use of mode of action data whenever possible. In the current jargon of cancer risk assessment, identifying the mechanism of action of a chemical implies a comprehensive understanding of every event in the process by which the chemical produces tumors in a particular organism. Knowledge of the mode of action suggests that one understands in general the critical events in that process, but not necessarily the details. There is no carcinogen for which the mechanism of action is fully known; thus, the new U.S. EPA guidelines do not propose such an unrealistic standard. The guidelines state: "While the exact mechanism of action of an agent at the molecular level may not be clear from existing data, the available data will often provide support for deducing the general mode of action. Under these guidelines, using all of the available data to arrive at a view ofthe mode of action supports both characterization of human hazard potential and assessment of dose response relationships" (11) .
The following section of this paper briefly highlights two cases in which consideration of the mode of action is already impacting the qualitative assessment of cancer risks. The proposed guidelines also offer new approaches to the quantitative assessment of cancer risks, including the consideration of mode A similar weight-of-evidence evaluation has recently been applied to understanding the relevance of findings of urinary bladder tumors in rodents (17) . Summaries by Gold et al. (18) and Huff et al. (19) Careful examination of available scientific information suggests the following model to explain findings of urinary bladder tumors in rats exposed to nongenotoxic agents. Relative to humans, the urine of rodents is high in osmolality (21) and rich in protein content (22 (24) . In humans, the anatomical orientation of the bladder is such that stones are apt to be voided or, if retained, the associated discomfort typically results in their removal by medical intervention. Epidemiologic studies suggest that the presence of calculi is only weakly associated with the occurrence of human bladder tumors (25) .
This weight-of-evidence analysis suggests that findings in rodents of bladder tumors associated with calculi may be of diminished concern for human health risk assessment. Indeed, this model is likely to be reflected in U.S. EPA policy relative to the interpretation of such lesions (12) . In order to support such a mode of action and the suggestion of diminished concern, an investigator would need to carefully characterize urine, precipitate, and stone chemistry; test agent metabolism, distribution, and excretion; and establish the dose dependency of the observations. Because urine chemistry is influenced by water consumption, diet, time of day, and other factors (21, 22) (26, 28) , but the uncertainty in this estimate is such that the risk characterization usually states that the true risk may actually be zero (7) .
The controversy that has developed in recent years over cancer risk assessment and the resultant risk management and regulatory decisions in the United States derives, in large measure, from this uncertainty and from variability in the estimates. Our inability to accurately estimate risks at low doses, based on data from lifetime animal studies conducted at much higher doses, is a multifaceted problem that has stimulated considerable discussion and research (8, 9, 29, 30, 31) , and this review can only mention some of the issues that are shaping the debate.
One issue that has attracted a great deal of attention is: What is the most appropriate expression of the output of a cancer dose response or risk assessment? Some have argued that the 95th percentile upper bound on a risk estimate that already incorporated a number of conservative default assumptions was overly conservative and was leading to risk estimates that were too high and regulatory standards (e.g., target cleanup levels) that were too stringent (32, 33 (34) (35) (36) .
A problem with relying solely on estimates of central tendency is that they tend to be unstable; i.e., in extrapolating from experimental animal tumor data to risks in the one-in-a-million range, the maximum likelihood estimate can be highly sensitive to very small changes in tumor incidence that occur as normal variability in animal studies. For example, Kodell and Park (37) have shown that increasing the number of animals with tumors from 1 of 50 to 3 of 50 in the mid-dose level of a three-dose level (plus controls) study can decrease the LMS maximum likelihood estimate of the dose corresponding to a 106 risk by more than 100-fold.
Thus, a consensus has developed within the regulatory risk assessment community that risk estimates derived from mathematical models like the LMS model must be expressed as more than a single number (9) . Several possible ways to express the estimates have been suggested. These include the presentation of some estimate of central tendency along with the upper and lower bounds (38) , the application of Monte Carlo analysis to generate an overall probability distribution for the risk estimates (39) (40) (41) (42) (43) , and other probabilistic approaches (44) (45) (46) (11) , the ED1o will be based on tumor incidence data from a rodent bioassay. However, ancillary data also may be used to extend the dose-response curve below the dose range in which tumors are observed, if the ancillary data can be clearly linked to the carcinogenic response. For example, the dose-dependent formation of DNA adducts of the chemical may be quantifiable at levels below the range in which an increased incidence of tumors is detectable. Such data may be used to extend the doseresponse curve for tumors if there is a high degree of confidence that the formation of these adducts is a requisite step in the development of the tumors in question and will display the same dose response as the tumor data at low doses (48) (49) (50) (51) . Many other biomarkers and preneoplastic changes have been reported that may be evaluated on a case-by-case basis for use in extending the dose-response curve (52) (53) (54) (55) (56) (57) (58) . However, the dose-dependent link between the biomarker and tumor end point must be firmly established.
The shape of the cancer dose-response curve at low doses has been a topic of much theoretical discussion and debate. For DNA-reactive carcinogens, it has been argued that their additivity to the background rate of ongoing carcinogenic processes predicts that the dose-response curve will be linear at low doses (59-61). Lutz (62) argued that "the presence of endogenous DNA damage implies that exogenous DNA-carcinogen adducts give rise to an incremental damage that is expected to be proportional to the carcinogen dose at the lowest levels." This, of course, says nothing about the doseresponse relationship at higher doses where curvature may occur due to saturation of critical metabolic pathways or DNA repair mechanisms, or where cytotoxicity may occur or cell proliferation may be induced (31, (63) (64) (65) (66) (67) (68) . In addition, there is a body of experimental data that suggests that exposure to low levels of some carcinogens, including ionizing radiation, may induce and enhance the efficiency of general repair mechanisms, and the debate over this potentially beneficial (hormetic) effect is drawing increasing attention (69) (70) (71) (72) (73) .
For rodent carcinogens that are functionally nongenotoxic (i.e., do not react directly with DNA in inducing tumors), new risk assessment paradigms are being proposed, based on information on the mode of action, that use a "margin of exposure" analysis analogous to that used commonly for noncancer endpoints. In such cases, "the risk is not extrapolated as a probability of an effect at low doses" (11) . Rather, estimated human exposure levels are compared with the lower 95% confidence limit on the ED1o from the animal carcinogenicity study or other studies of precursor effects (with doses adjusted for the animal-to-human extrapolation). This margin of exposure analysis does not necessarily require the demonstration of a true threshold for the carcinogenic process but rather a sufficiently clear understanding of the mode of action to support the presumption of an effective threshold (highly nonlinear dose response) (17, (74) (75) (76) (77) . It has been suggested that experimental proof of a biological threshold is somewhat akin to proving a negative (78) . Indeed, the caution by Melnick et al. (16) reliance on oversimplified classification schemes" (such as those postulating thresholds) is well taken and is one of the issues that led the U.S. EPA to discard the alphanumeric classification scheme for carcinogens in favor a narrative description of the weight of the evidence (11) .
The new U.S. EPA guidelines call for a fuller understanding of the carcinogenic process and the use of all of the information available, rather than sole reliance on rodent tumor data. Clearly, the way forward will bring with it pitfalls and problems as toxicologists attempt to evaluate and assimilate the rapidly advancing knowledge base in fundamental cancer biology, hormonal effects (79, 80) , chemical interactions with cellular components, and toxicokinetics (57) in their risk assessments. The temptation to oversimplify the complex may still lead to over-or underestimates of the carcinogenic potential of individual chemicals for humans. In the final analysis, the actual impact of the increasing emphasis on delineation of mechanisms and modes of action on regulatory risk assessment for carcinogens will be an important benchmark in assessing the value and usefulness of the proposed guidelines.
More complex biologically based mathematical models of the carcinogenic process also have been developed, but early hopes that these models might be useful in estimating small risks at low doses have not been realized as yet (81) . Two general types of these models are the timeindependent models exemplified by the work of Moolgavkar and others (82) (83) (84) (85) and the time-dependent models exemplified by the work of Ellwein and Cohen (66, (86) (87) (88) (89) Good animal husbandry is critical to the success of any animal study and thus figured prominently in the establishment of the NTP in vivo toxicity and carcinogenicity testing procedures. In the interest of good husbandry, an ad libitum feeding protocol was established for laboratory rodents to ensure the availability of adequate amounts of food on demand while obviating the need for, and costs associated with, individualized feed rationing and scheduled feedings. In recent years, it has become apparent that among rodents used in 2-year bioassays, survival has decreased, obesity increased, and the incidence of background tumors and intercurrent diseases have increased relative to their counterparts in studies conducted during the 1960s and 1970s (113) (114) (115) (116) . Among control animals, these observations confound the interpretation of the results of the bioassay and call into question the reliability, reproducibility, and predictability of the procedure (117) .
Careful examination of data from NTP-sponsored and NTP-conforming studies has revealed a consistent pattern of increased rate of animal body weight gain relative to the historical data (113, 118, 119) . Moreover, Keenan et al. (120, 121) report considerable intra-and interlaboratory variability in body weights of animals maintained under nominal ad libitum feeding protocols. Differences in feeding device configuration and accessibility accounted for a nearly 2-fold difference in body weight between same-age animals fed ad libitum. These and other studies suggested that animals of lower body weight exhibited greater 2-year survival, fewer background tumors, and less intercurrent disease than their obese counterparts (120, 121) . Similar findings occur when animals fed a portion-controlled ration of nutritionally sufficient feed are compared with ad libitum fed animals (122, 123) . The relationship between food intake and weight gain is further confounded by genetic drift in rodent breeding colonies because of selection for rapid growth and large litter size (124, 125) to satisfy the demand for test animals.
These findings pose a considerable challenge to the NTP and to the risk assessment community. If One proposal currently in front of the scientific community is to screen for chemical carcinogens in two genetically modified strains of mice, the TG.AC transgenic animal and the p53 knockout mouse (131) . TG.AC mice carry an activated vHa-ras oncogene that is expressed primarily in the skin (133) . This gene is activated in transformed cells from various human and mouse tumors (134) and the expression of the activated form of the gene in TG.AC mice is thought to be functionally equivalent to an initiated animal in the context of the multistage model of carcinogenesis (132) . The p53 tumor suppressor gene is inactivated in a variety of human and mouse tumors (135, 136 Technology does exist to regulate transgenes to achieve organ-specific expression of the gene product (139) , but it is probably premature to factor such approaches into carcinogen screening.
Considerable uncertainty surrounds the interpretation of findings of chemically induced tumors in genetically modified animals. There is concern that the greater sensitivity of the genetically modified mice may lead to a high rate of false positive results. In the context of prospective studies, it is unclear how to distinguish a false positive from a true positive and, indeed, the appropriate standard against which to base such a distinction. As has been pointed out by many observers, the 2-year carcinogenicity bioassay has never been validated, and while human cancer may constitute the gold standard, few data are available to use in such a fashion.
Another important issue is how, if appropriate, to phase in the use of screening studies in genetically altered animals. As currently configured, the four-cell bioassay provides for increased confidence in predicting human risk if positive results are obtained in both species and/or animals of each sex. Some have proposed replacing the 2-year mouse study with short-term studies in genetically modified mice. Clearly more studies will be needed to support such an approach. Although many anticipate the development and commercialization of transgenic rats, most, if not all, of these issues will apply to those animals as well.
The International Conference on Harmonization, an international coordinating body composed of representatives of pharmaceutical manufacturers and regulatory agencies, recently proposed that carcinogenicity testing in genetically modified mice or other assay systems be substituted for the conventional 2-year mouse bioassay (139) . This proposal has stimulated a coordinated, international multilaboratory study to examine a number of the issues raised in the preceding paragraphs. The study is being coordinated by the ILSI Health and Environmental Sciences Institute.
The technology and techniques for genetic manipulation are rapidly evolving, as is understanding of the genetic basis for cancer susceptibility (11, 140, 141) . This suggests that new animal models, each offering unique insights into the carcinogenic process(es), will come to the attention of the toxicology and risk assessment communities. Indeed, it is already apparent that the cancer profile of hemizygous p53 knockout mice differs depending upon the strain of mouse in which the p53 gene is inactivated (142 
